Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tepezza in Diffuse Cutaneous Systemic Sclerosis
NCT04478994Phase 1Terminated
- Sponsor
- Amgen
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in diffuse cutaneous systemic sclerosis (dcSSc) comparing Tepezza with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 24 weeks. Started Nov 2021; status: terminated.
02
Drugs
teprotumumab
03
Conditions
diffuse cutaneous systemic sclerosis (dcSSc)
Beyond the preview
Go deeper on NCT04478994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04478994.